COMPASS Pathways plc (CMPS) Stock Price & Analysis
COMPASS Pathways plc (CMPS) closed at USD 11.18 on Friday, October 23, 2026, down 3.87% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 11.63; the Oct 23, 2026 session ranged USD 11.03–11.52 on volume of 1,158,790 shares. Market capitalization is $1.55B, with a 52-week range of USD 4.88–15.87 (NMS). Source: Nexqual, retrieved October 24, 2026 at 01:09 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CMPS.md
Key facts (CMPS)
- Analysts: Buy (mean 1.88 on a 1–5 scale) (16 analysts), mean target USD 23.75 (range 13–65).
- Total return with dividends: 1Y +85.2% vs S&P 500 +14.0%; 5Y -73.5% vs S&P 500 +76.9%.
- Next earnings: 2026-11-03, EPS estimate USD -0.33, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CMPS)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$83.2M | -$110M | -$137M | -$178M | -$179M | -$182M |
| Net income | -$71.7M | -$91.5M | -$118M | -$155M | -$288M | -$394M |
| EPS (diluted) | -$1.79 | -$2.16 | -$2.32 | -$2.30 | -$3.08 | — |
| Free cash flow | -$68.1M | -$106M | -$97.4M | -$119M | — | — |
| Cash + short-term investments | $273M | $143M | $220M | $165M | $150M | — |
| Total debt | — | $0K | $28.8M | $30.2M | $31.6M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CMPS)
P/B 18.3x · Earnings yield -25.46% · Net cash $383M · EV $1.17B
Analysts (CMPS)
Consensus Buy (mean 1.88 on a 1–5 scale), 16 analysts; mean target USD 23.75 (low 13, high 65).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-07 | HC Wainwright & Co. | Target lowered | Buy | $70 → $65 |
| 2026-08-06 | Morgan Stanley | Target raised | Overweight | $17 → $18 |
| 2026-08-06 | RBC Capital | Target lowered | Outperform | $22 → $21 |
| 2026-08-06 | B. Riley Securities | Target raised | Buy | $17 → $22 |
| 2026-07-27 | Wells Fargo | Initiated | Equal-Weight | $13 |
| 2026-07-08 | HC Wainwright & Co. | Reiterated | Buy | $70 |
| 2026-07-08 | Evercore ISI Group | Upgrade | In-Line → Outperform | $8 → $21 |
| 2026-07-08 | Stifel | Target raised | Buy | $14 → $21 |
| 2026-07-07 | Morgan Stanley | Reiterated | Overweight | $17 |
| 2026-07-07 | Oppenheimer | Reiterated | Outperform | $20 |
| 2026-07-07 | BTIG | Target raised | Buy | $14 → $25 |
| 2026-06-26 | Canaccord Genuity | Target raised | Buy | $18 → $20 |
Total return (dividends reinvested) (CMPS)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +85.2% | -73.5% |
| S&P 500 (SPY) | +14.0% | +76.9% |
| Per year | +85.9% | -23.4% |
| Volatility (annualized) | 85.5% | 77.6% |
| Max drawdown | -38.2% (Feb 2026→Mar 2026) | -94.5% (Nov 2021→Mar 2025) |
CMPS suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Hercules Capital, Inc. (HTGC) | “Our Loan Agreement with Hercules includes, and any future debt financing, if available, may involve agreements that include affirmative and negative restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business.” |
| Partner | Delix Therapeutics | “We have a strategic investment in Delix Therapeutics, Inc., a clinical-stage neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological disorders.” |
| Partner | Neuronetics, Inc. (STIM) | “In order to ensure we understand implementation challenges, we have entered into a number of collaboration agreements with numerous different types of health care delivery systems in the U.S. We have entered into collaboration agreements with Greenbrook Mental Wellness Centers (acquired by Neuronetics, Inc. in December 2024), a leading provider of interventional psychiatric treatments in the U.S.;” |
Quoted from the company's 10-K filed Mar 24, 2026.
CMPS company outlook (results filed Aug 5, 2026)
- “The current cash position is expected to be sufficient to fund operating expenses and capital expenditure requirements into 2028.”
Quoted word-for-word from the SEC 8-K results press release.
CMPS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.33 | $-0.34 | -4.3% | $0 | 4 |
| Next quarter (ends Dec 2026) | $-0.39 | $-0.41 | -5.5% | $0 | 4 |
| Current fiscal year (ends Dec 2026) | $-1.50 | $-0.99 | +51.3% | $0 | 4 |
| Next fiscal year (ends Dec 2027) | $-1.43 | $-1.06 | +35.6% | $39.7M | 3 |
CMPS options: expected move
Options price a move of about ±17.1% (±$1.92) by Nov 20, 2026, which includes earnings on Nov 3, 2026. Over the last 8 reports the stock moved ±10.3% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 83.1% | ±17.1% |
| Dec 18, 2026 | 56 | 79.0% | ±24.5% |
| Jan 15, 2027 | 84 | 84.8% | ±32.1% |
| Feb 19, 2027 | 119 | 78.1% | ±35.2% |
| May 21, 2027 | 210 | 92.6% | ±54.5% |
30-day implied volatility 77.6% vs 58.8% realized over the last 30 trading days. Put/call ratio (volume) 0.15. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 24, 2026 at 01:09 UTC)
| Price | USD 11.18 |
|---|---|
| Change | ▼ 3.87% (down) |
| Previous Close | USD 11.63 |
| Open | USD 11.45 |
| Day Range | USD 11.03 – 11.52 |
| 52-Week Range | USD 4.88 – 15.87 |
| Volume | 1,158,790 shares |
| Market Cap | $1.55B |
| Exchange | NMS |
Technical Analysis (CMPS)
Nexqual's technical model rates CMPS "STRONG SELL" based on 0 bullish and 5 bearish signals across 126 daily candles, as of October 24, 2026 at 01:09 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 46.05 (neutral) |
| vs SMA50 | Below (USD 13.15) |
| MACD | -0.5 (negative) |
Analyst Ratings (CMPS)
Wall Street analysts rate CMPS "Buy" based on 16 analysts, with a mean price target of USD 23.75 (range USD 13–65), per Nexqual as of October 24, 2026 at 01:09 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 16 |
| Mean Target | USD 23.75 |
| High Target | USD 65 |
| Low Target | USD 13 |
| Buy / Hold / Sell | 15 / 1 / 0 |
Earnings (CMPS)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD -0.33 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.36 vs est -0.34 ▼ miss |
| 2026-03-31 | USD -0.31 vs est -0.32 ▲ beat |
| 2025-12-31 | USD -0.61 vs est -0.39 ▼ miss |
| 2025-09-30 | USD -0.38 vs est -0.41 ▲ beat |
Source: Nexqual, October 24, 2026 at 01:09 UTC.
Financials & Fundamentals (CMPS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -319.07% |
| Debt / Equity | 0.65 |
| Current Ratio | 1.3 |
| Total Cash | $433.30M |
| Total Debt | $54.63M |
Source: Nexqual, October 24, 2026 at 01:09 UTC.
Financial Health Score (CMPS)
Nexqual rates COMPASS Pathways plc's overall financial health "Weak" across five dimensions, as of October 24, 2026 at 01:09 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Solid — $433M cash and investments vs $51M debt (Jun 2026, SEC), net cash |
| Cash Flow | Weak — Operating cash flow -$157M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -319%, ROA -29.1% |
Ownership (CMPS)
| Insider Ownership | +7.62% |
|---|---|
| Institutional Ownership | +69.19% |
| Shares Outstanding | 138.48M |
| Float | 106.97M |
| Short % of Float | +12.46% |
Source: Nexqual, October 24, 2026 at 01:09 UTC.
Leadership (CMPS)
COMPASS Pathways plc is led by Kabir Kumar Nath M.A., CEO & Executive Director, per Nexqual as of October 24, 2026 at 01:09 UTC.
| CEO & Executive Director | Kabir Kumar Nath M.A. |
|---|---|
| Chief Financial Officer | Teri Loxam |
| Senior Vice President of Investor Relations | Stephen D. Schultz |
Major Backers & Investors (CMPS)
Notable institutional backers of COMPASS Pathways plc include Deep Track Capital, Lp, RTW Investments LP, BIT Capital GmbH, according to Nexqual as of October 24, 2026 at 01:09 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Deep Track Capital, Lp | 8.78% |
| RTW Investments LP | 7.73% |
| BIT Capital GmbH | 4.58% |
| Tang Capital Management, LLC | 3.61% |
| Two Sigma Investments, LP | 3.23% |
| Marshall Wace LLP | 3.13% |
| ARK Invest | 2.49% |
| Point72 Asset Management, L.P. | 1.89% |
Source: Nexqual, October 24, 2026 at 01:09 UTC.
From COMPASS Pathways plc's Latest SEC 10-K Filing (filed 2026-03-24)
Key Strengths & Strategy (as disclosed to the SEC)
- COMP360 is our proprietary psilocybin formulation that includes our pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity.
Legal & Regulatory Risks (Item 1A, quoted)
- We may become subject to U.S. federal and state forfeiture laws which could negatively impact our business operations.
- We are subject to certain tax risks and treatments that could negatively impact our results of operations.
- We may be unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments or benefit from favorable UK tax legislation.
- We may benefit in the future from the UK's "patent box" regime, which allows certain profits attributable to revenue from patented products (and other qualifying income) to be taxed at an effective rate of 10% by giving an additional tax deduction.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AGL | agilon health, inc. | USD 89.71 | ▼ 0.64% |
| PNTG | The Pennant Group, Inc. | USD 41.88 | ▼ 0.83% |
| SNDA | Sonida Senior Living, Inc. | USD 33.82 | ▼ 0.15% |
| NUTX | Nutex Health Inc. | USD 209.59 | ▲ 1.7% |
| HCSG | Healthcare Services Group, Inc. | USD 25.3 | ▲ 2.06% |
| ARDT | Ardent Health, Inc. | USD 12.27 | ▼ 0.73% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 01:09 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt